News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Nxera Pharma Reaches Key Development Milestone in Partnership with Eli Lilly for Metabolic Disease Treatments
Monday, June 02, 2025Nxera Pharma Co Ltdhas reached a significant development milestone as part of its ongoing multitarget collaboration and licence agreement with Eli Lilly and Company This achievement relates to research efforts
Mabwell Gains NMPA Approval for Albipagrastim Alfa for Injection (MAILISHENG)
Saturday, May 31, 2025Mabwell SH an innovationfocused biopharmaceutical company has received marketing approval from the National Medical Products Administration NMPA in China for Albipagrastim alfa for Injection marketed under the trade name MAILISHENG The drug developed...
Beam Therapeutics Receives U.S. FDA Orphan Drug Designation for BEAM-302 to Treat Alpha-1 Antitrypsin Deficiency
Friday, May 30, 2025Beam Therapeutics Inc a biotechnology firm focused on precision genetic medicines through base editing has received orphan drug designation from the US Food and Drug Administration FDA for its investigational therapy
Sevabertinib (BAY 2927088) Receives FDA Priority Review for HER2-Mutant Non-Small Cell Lung Cancer
Thursday, May 29, 2025Bayers investigational therapy sevabertinib BAY has been granted Priority Review by the US Food and Drug Administration FDA for the treatment of adults with advanced nonsmall cell lung cancer
Candel Therapeutics Granted FDA RMAT Designation for CAN-2409 in Prostate Cancer Treatment
Thursday, May 29, 2025Candel Therapeutics has received Regenerative Medicine Advanced Therapy RMAT designation from the US Food and Drug Administration FDA for CAN its lead biological immunotherapy candidate
Alvotech and Advanz Pharma Strengthen Partnership to Include Three New Biosimilars in Europe
Thursday, May 29, 2025Alvotech a global biotechnology firm focused on developing and producing biosimilar medicines and Advanz Pharma a UKbased pharmaceutical company specialising in hospital specialty and rare disease treatments
Biogen and City Therapeutics Begin Research Collaboration on RNAi-Based Therapies
Wednesday, May 28, 2025Biogen Inc and City Therapeutics a privately owned biopharmaceutical company focused on RNA interference RNAi therapies have entered into a strategic research partnership to develop selected RNAibased treatments
Coherus and STORM Therapeutics Begin Clinical Study of STC-15 with LOQTORZI® for Multiple Cancers
Wednesday, May 28, 2025Coherus BioSciences Inc has entered into a clinical collaboration with STORM Therapeutics Ltd to assess a new cancer treatment approach The study will test the combination of STC a METTL inhibitor and LOQTORZI
Imfinzi Receives CHMP Recommendation in the EU as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer
Tuesday, May 27, 2025Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency for use in adult patients with resectable muscleinvasive bladder cancer MIBC The recommendation covers its use alongside gemcitabine
Bio-Thera and Hikma Receive FDA Approval for STARJEMZA®, a Biosimilar to Stelara®
Tuesday, May 27, 2025BioThera Solutions Ltd a commercialstage biopharmaceutical company and Hikma Pharmaceuticals PLC including its US subsidiary have received approval from the US Food and Drug Administration FDA for STARJEMZA ustekinumabhmny Injection
